ThermoGenesis Corp. Initiates Shipments of Thrombin Processing Devices(TM) (TPD(TM)) To Biomet, Inc.
17 August 2005 - 1:00AM
PR Newswire (US)
Agreement Allows Biomet to Immediately Market Their Gravitational
Platelet Separation System (GPS) in Europe, Canada and Asia as a
Fully Autologous Product RANCHO CORDOVA, Calif., Aug. 16
/PRNewswire-FirstCall/ -- ThermoGenesis Corp. (NASDAQ:KOOL)
announced today that the Company has begun shipping its CE marked
TPD to the Biomet, Inc. (NASDAQ:BMET) subsidiary, Cell Factor
Technologies, Inc. (CFT). CFT will use the TPD to prepare
autologous thrombin while a customized centrifugal thrombin device,
named Clotalyst(TM), is under development by ThermoGenesis. The TPD
disposable kit, which produces stable, activated thrombin from the
patient's own blood in less than 30 minutes, will enable CFT to
immediately address this demand in Europe, Canada, and Asia.
Approximately $180 million of thrombin annually is consumed
worldwide as a blood clotting enzyme that surgeons use for
hemostasis, the treatment of pseudoaneurysms, and to form "platelet
gels" for the treatment of damaged tissue. Kevin Simpson, President
& COO of ThermoGenesis noted, "We are pleased to support
Biomet's subsidiary CFT by supplying them the TPD to immediately
address the many potential thrombin applications in their
orthopedic, spinal, maxillofacial, and dental reconstructive
markets. Access to the TPD allows CFT to immediately satisfy the
demand in various countries for an autologous thrombin, while
development of the Clotalyst device as a seamless adjunct to their
GPS platelet system progresses. This novel disposable allows
surgeons to treat patients with autologous thrombin (thrombin
manufactured from their own blood), instead of bovine thrombin."
Joel Higgins, Vice President of Technical Affairs for CFT,
commented, "We are pleased to be able to immediately satisfy the
demand for a completely "autologous" platelet product. The initial
reaction of our customers in Europe and Canada appears favorable."
Regulatory Status ThermoGenesis has received the right to affix the
CE Mark to the TPD from its Notified Body. The regulatory pathway
in the United States will require a Pre-Market Approval Application
for the platelet gel product of which autologous thrombin is a
component. About Biomet Inc. Biomet, Inc. and its subsidiaries
design manufacture and market products used primarily by
musculoskeletal medical specialists in both surgical and
non-surgical therapy. The company's product portfolio encompasses
reconstructive products, including orthopedic joint replacement
devices, bone cements and accessories, and dental reconstructive
implants; fixation products, including electrical bone growth
stimulators, internal and external orthopedic fixation devices,
craniomaxillofacial implants and bone substitute materials; spinal
products, including spinal stimulation devices, spinal hardware and
orthobiologics; and other products, such as arthroscopy products
and softgoods and bracing products. Headquartered in Warsaw,
Indiana, Biomet and its subsidiaries currently distribute products
in more than 100 countries. About ThermoGenesis Corp. After
extensive research, ThermoGenesis Corp.'s newly introduced
technology platforms lead the world in their ability to produce
biological products from single units of blood. Umbilical cord
blood banks are utilizing the Company's BioArchive(R) System as a
critical enabling technology for cryogenic archiving of stem cells
for transplant, while its CryoSeal(R) FS System is used to prepare
hemostatic and adhesive surgical sealants from patient blood in
about an hour. ThermoGenesis Corp. has been a leading supplier of
state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to
hospitals and blood banks since 1992. The statements contained in
this release which are not historical facts are forward-looking
statements that are subject to risks and uncertainties that could
cause actual results to differ materially from those expressed in
the forward-looking statements, including, but not limited to,
certain delays beyond the company's control with respect to market
acceptance of new technologies and products, delays in testing and
evaluation of products, and other risks detailed from time to time
in the Company's filings with the Securities and Exchange
Commission. DATASOURCE: ThermoGenesis Corp. CONTACT: Kevin Simpson
of ThermoGenesis Corp., +1-916-858-5100 Web site:
http://www.thermogenesis.com/
Copyright
Biomet (NASDAQ:BMET)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biomet (NASDAQ:BMET)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Biomet (MM) (NASDAQ): 0 recent articles
More Biomet (MM) News Articles